Details of Disease

General Information of Disease (ID: DIS8G07K)

Disease Name	Gastritis
Synonyms	erosive gastropathy; erosive gastritis; acute gastric mucosal erosion; stomach inflammation; inflammation of stomach; gastritis (disease); gastritis
Disease Class	DA42: Gastritis
Definition	Inflammation of the stomach.
Disease Hierarchy	DIS184KT: Skin inflammation DISWD40R: Disease DISJLJZ9: Stomach disease DIS8G07K: Gastritis
ICD Code	ICD-11 ICD-11: DA42 Expand ICD-11 'DA42 Expand ICD-10 'K29; 'K29.1; 'K29.5; 'K29.6; 'K29.7
Disease Identifiers	MONDO ID MONDO_0004966 MESH ID D005756 UMLS CUI C0017152 MedGen ID 4843 HPO ID HP:0005263 SNOMED CT ID 4556007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Methantheline	DM8X4A1	Approved	Small molecular drug	[1]
Ornoprostil	DM1DKYL	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SK-MS10	DMFB782	Phase 2	NA	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
KDM-1001	DM783OD	Investigative	NA	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 20 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HDGF	TTKGV26	Limited	Biomarker	[4]
ADGRL1	TTM5OJN	moderate	Genetic Variation	[5]
ATP4A	TTF1QVM	moderate	Biomarker	[6]
CACNA1E	TTYRP0M	moderate	Biomarker	[7]
CHIA	TTJB1O0	moderate	Biomarker	[8]
LCT	TTA0OSE	moderate	Biomarker	[9]
NFKBIA	TTSHAEB	moderate	Therapeutic	[10]
REG4	TTVZEHU	moderate	Altered Expression	[11]
CCKBR	TTVFO0U	Strong	Biomarker	[12]
CYP2C19	TTZ58XG	Strong	Genetic Variation	[13]
DEFB4A	TTIVY12	Strong	Biomarker	[14]
FOXP3	TT1X3QF	Strong	Altered Expression	[15]
IL11	TTGUYTR	Strong	Altered Expression	[16]
IL32	TTD4G7L	Strong	Altered Expression	[17]
LTBR	TTFO0PM	Strong	Altered Expression	[18]
MADCAM1	TTBD6I7	Strong	Biomarker	[19]
MUC5AC	TTEL90S	Strong	Biomarker	[20]
PSCA	TT9T4AV	Strong	Genetic Variation	[21]
RNF43	TTD91BL	Strong	Genetic Variation	[22]
SELL	TT2IYXF	Strong	Biomarker	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	moderate	Altered Expression	[23]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SMOX	DEOH5V3	Strong	Biomarker	[24]
UGT1A6	DESD26P	Strong	Genetic Variation	[25]
------------------------------------------------------------------------------------

This Disease Is Related to 35 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD177	OTS79FNF	Limited	Biomarker	[26]
FTL	OTYQA8A6	Limited	Biomarker	[27]
G3BP2	OTAWW3KI	Limited	Altered Expression	[28]
GKN1	OT7ZYFQ9	Limited	Altered Expression	[29]
IREB2	OT747D24	Limited	Altered Expression	[27]
NOXO1	OTW29FB4	Limited	Altered Expression	[30]
RABEP2	OTO61X27	Limited	Altered Expression	[28]
SIGLEC8	OTQ5TRRV	Limited	Biomarker	[31]
SPART	OTIVOS2I	Limited	Posttranslational Modification	[32]
A4GNT	OT8GOL3T	moderate	Biomarker	[33]
ADGRL2	OTCXD2YR	moderate	Genetic Variation	[5]
ATP4B	OTIP2EYJ	moderate	Biomarker	[6]
CHST2	OTV11IZF	moderate	Altered Expression	[19]
CLIP4	OT75KVQK	moderate	Biomarker	[34]
DEFA5	OT95CBQ9	moderate	Biomarker	[35]
DEFB103B	OT8RWY64	moderate	Biomarker	[14]
ELMO1	OTY2ORXK	moderate	Biomarker	[34]
GTF2H4	OTPD1DIU	moderate	Genetic Variation	[36]
HLA-DPA1	OT7OG7Y2	moderate	Biomarker	[37]
L1TD1	OTB2W20Y	moderate	Posttranslational Modification	[38]
MBD3	OTRL76H5	moderate	Altered Expression	[39]
MDH2	OT7364GY	moderate	Altered Expression	[40]
PITX1	OTA0UN4C	moderate	Biomarker	[41]
RTL10	OTHGB81W	moderate	Biomarker	[42]
S100A2	OTTGHJ1H	moderate	Altered Expression	[43]
TP53INP1	OT2363Z9	moderate	Altered Expression	[44]
CBLIF	OTNE20WU	Strong	Altered Expression	[45]
CDX1	OTOHTMJE	Strong	Altered Expression	[46]
CDX2	OTCG4TSY	Strong	Biomarker	[47]
DEFB1	OT5SV0E4	Strong	Biomarker	[35]
NOX1	OTZPJQCC	Strong	Altered Expression	[30]
PLCE1	OTJISZOX	Strong	Genetic Variation	[48]
REM1	OTUXL0HC	Strong	Biomarker	[49]
TFF2	OTRXB19X	Strong	Altered Expression	[50]
HSPA14	OTZCA5LK	Definitive	Biomarker	[51]
------------------------------------------------------------------------------------


⏷ Show the Full List of 35 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01578811) Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis. U.S. National Institutes of Health.
3	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
4	Hepatoma-derived growth factor participates in Helicobacter Pylori-induced neutrophils recruitment, gastritis and gastric carcinogenesis.Oncogene. 2019 Sep;38(37):6461-6477. doi: 10.1038/s41388-019-0886-3. Epub 2019 Jul 22.
5	A preliminary study on the genetic profile of cag pathogenicity-island and other virulent gene loci of Helicobacter pylori strains from Turkey.Infect Genet Evol. 2007 Jul;7(4):509-12. doi: 10.1016/j.meegid.2007.03.002. Epub 2007 Mar 24.
6	Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients.Clin Transl Gastroenterol. 2017 Jan 19;8(1):e215. doi: 10.1038/ctg.2016.71.
7	Roux-en-Y or Billroth II Reconstruction After Radical Distal Gastrectomy for Gastric Cancer: A Multicenter Randomized Controlled Trial.Ann Surg. 2018 Feb;267(2):236-242. doi: 10.1097/SLA.0000000000002229.
8	CHIT1 and AMCase expression in human gastric mucosa: correlation with inflammation and Helicobacter pylori infection.Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1119-26. doi: 10.1097/MEG.0b013e328329742a.
9	Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.Eur J Gastroenterol Hepatol. 2003 Jan;15(1):27-33. doi: 10.1097/00042737-200301000-00006.
10	[Serumimmunological study of moxibustion on helicobacter pylori gastritis in rats].Zhongguo Zhen Jiu. 2014 Aug;34(8):783-90.
11	The role of Reg IV gene and its encoding product in gastric carcinogenesis.Hum Pathol. 2010 Jan;41(1):59-69. doi: 10.1016/j.humpath.2009.06.013. Epub 2009 Sep 8.
12	Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis.BMC Complement Altern Med. 2018 Nov 1;18(1):292. doi: 10.1186/s12906-018-2356-9.
13	First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.World J Gastroenterol. 2015 Dec 28;21(48):13548-54. doi: 10.3748/wjg.v21.i48.13548.
14	Human beta-defensin-3 induction in H. pylori-infected gastric mucosal tissues.World J Gastroenterol. 2006 Sep 28;12(36):5793-7. doi: 10.3748/wjg.v12.i36.5793.
15	Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection.Microb Pathog. 2017 Sep;110:165-175. doi: 10.1016/j.micpath.2017.06.040. Epub 2017 Jun 27.
16	Interplay Between Helicobacter pylori Infection, Interleukin-11, and Leukemia Inhibitory Factor in Gastric Cancer Among Egyptian Patients.J Interferon Cytokine Res. 2018 Nov;38(11):517-525. doi: 10.1089/jir.2018.0065. Epub 2018 Oct 31.
17	Elevated interleukin-32 expression is associated with Helicobacter pylori-related gastritis.PLoS One. 2014 Mar 14;9(3):e88270. doi: 10.1371/journal.pone.0088270. eCollection 2014.
18	Increased LIGHT expression and activation of non-canonical NF-B are observed in gastric lesions of MyD88-deficient mice upon Helicobacter felis infection.Sci Rep. 2019 May 7;9(1):7030. doi: 10.1038/s41598-019-43417-x.
19	Induction of high endothelial venule-like vessels expressing GlcNAc6ST-1-mediated L-selectin ligand carbohydrate and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) in a mouse model of "Candidatus Helicobacter heilmannii"-induced gastritis and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.Helicobacter. 2010 Dec;15(6):538-48. doi: 10.1111/j.1523-5378.2010.00801.x.
20	Muc5ac null mice are predisposed to spontaneous gastric antro-pyloric hyperplasia and adenomas coupled with attenuated H. pylori-induced corpus mucous metaplasia.Lab Invest. 2019 Dec;99(12):1887-1905. doi: 10.1038/s41374-019-0293-y. Epub 2019 Aug 9.
21	Prostate stem cell antigen gene TT genotype and development of intestinal metaplasia in Helicobacter pylori infection.J Dig Dis. 2016 Jan;17(1):20-7. doi: 10.1111/1751-2980.12309.
22	Mutated Rnf43 Aggravates Helicobacter Pylori-Induced Gastric Pathology.Cancers (Basel). 2019 Mar 16;11(3):372. doi: 10.3390/cancers11030372.
23	Pathophysiology and laboratory diagnosis of pernicious anemia.Immunol Res. 2017 Feb;65(1):326-330. doi: 10.1007/s12026-016-8841-7.
24	Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastric epithelial cells with DNA damage.Gastroenterology. 2014 Jun;146(7):1739-51.e14. doi: 10.1053/j.gastro.2014.02.005. Epub 2014 Feb 13.
25	The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin.J Pharm Pharm Sci. 2015;18(3):474-83. doi: 10.18433/j3fc7f.
26	CD177 Expression and Inflammation Grade in Helicobacter pylori-Infected Wild-Type and CD177(-/-) C57BL/6 Mice.Anal Cell Pathol (Amst). 2019 Apr 4;2019:9506863. doi: 10.1155/2019/9506863. eCollection 2019.
27	The role of transferrin receptor in the Helicobacter pylori pathogenesis; L-ferritin as a novel marker for intestinal metaplasia.Microb Pathog. 2019 Jan;126:157-164. doi: 10.1016/j.micpath.2018.10.039. Epub 2018 Oct 31.
28	Carcinogenic Helicobacter pylori Strains Selectively Dysregulate the In Vivo Gastric Proteome, Which May Be Associated with Stomach Cancer Progression.Mol Cell Proteomics. 2019 Feb;18(2):352-371. doi: 10.1074/mcp.RA118.001181. Epub 2018 Nov 19.
29	Helicobacter pylori inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway.Helicobacter. 2020 Feb;25(1):e12665. doi: 10.1111/hel.12665. Epub 2019 Oct 27.
30	NF-B-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells.Oncogene. 2019 May;38(22):4250-4263. doi: 10.1038/s41388-019-0702-0. Epub 2019 Jan 30.
31	Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis.JCI Insight. 2019 Oct 3;4(19):e126219. doi: 10.1172/jci.insight.126219.
32	Methylomics analysis identifies a putative STAT3 target, SPG20, as a noninvasive epigenetic biomarker for early detection of gastric cancer.PLoS One. 2019 Jun 13;14(6):e0218338. doi: 10.1371/journal.pone.0218338. eCollection 2019.
33	Usefulness of the real-time reverse transcription-polymerase chain reaction assay targeted to alpha1,4-N-acetylglucosaminyltransferase for the detection of gastric cancer.Lab Invest. 2003 Feb;83(2):187-97. doi: 10.1097/01.lab.0000057001.21187.a0.
34	Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies.Oncotarget. 2017 Jun 13;8(24):38501-38516. doi: 10.18632/oncotarget.16258.
35	Defensin-mRNA expression in the upper gastrointestinal tract is modulated in children with celiac disease and Helicobacter pylori-positive gastritis.J Pediatr Gastroenterol Nutr. 2010 Jun;50(6):596-600. doi: 10.1097/MPG.0b013e3181cd26cd.
36	Lymphotoxin receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner.Gut. 2017 Aug;66(8):1369-1381. doi: 10.1136/gutjnl-2015-310783. Epub 2016 Apr 13.
37	Contribution of major histocompatibility complex genes to susceptibility and resistance in Helicobacter pylori related diseases.Eur J Gastroenterol Hepatol. 1999 Aug;11(8):875-80. doi: 10.1097/00042737-199908000-00011.
38	LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis.Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2555-64. doi: 10.1158/1055-9965.EPI-08-0112.
39	Reduced mRNA expression levels of MBD2 and MBD3 in gastric carcinogenesis.Tumour Biol. 2014 Apr;35(4):3447-53. doi: 10.1007/s13277-013-1455-y. Epub 2013 Dec 13.
40	Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis.Biochem Pharmacol. 2008 Jun 1;75(11):2135-46. doi: 10.1016/j.bcp.2008.03.008. Epub 2008 Mar 22.
41	Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection.Eur J Pharm Biopharm. 2017 Feb;111:33-43. doi: 10.1016/j.ejpb.2016.11.007. Epub 2016 Nov 16.
42	BH3-only protein Bim is associated with the degree of Helicobacter pylori-induced gastritis and is localized to the mitochondria of inflammatory cells in the gastric mucosa.Int J Med Microbiol. 2015 Sep;305(6):553-62. doi: 10.1016/j.ijmm.2015.07.002. Epub 2015 Jul 9.
43	Clinical significance of altered S100A2 expression in gastric cancer.Oncol Rep. 2013 Apr;29(4):1556-62. doi: 10.3892/or.2013.2236. Epub 2013 Jan 15.
44	Difference of p53AIP1 mRNA expression in gastric mucosa between patients with gastric cancer and chronic gastritis infected with Helicobacter pylori.J Clin Gastroenterol. 2008 Apr;42(4):351-5. doi: 10.1097/MCG.0b013e318054493e.
45	T-bet(+) Cells Polarization in Patients Infected with Helicobacter pylori Increase the Risk of Peptic Ulcer Development.Arch Med Res. 2019 Apr;50(3):113-121. doi: 10.1016/j.arcmed.2019.07.005. Epub 2019 Aug 7.
46	Methylation-dependent activation of CDX1 through NF-B: a link from inflammation to intestinal metaplasia in the human stomach.Am J Pathol. 2012 Aug;181(2):487-98. doi: 10.1016/j.ajpath.2012.04.028. Epub 2012 Jun 27.
47	Activation of FXR promotes intestinal metaplasia of gastric cells via SHP-dependent upregulation of the expression of CDX2.Oncol Lett. 2018 May;15(5):7617-7624. doi: 10.3892/ol.2018.8342. Epub 2018 Mar 23.
48	PSCA and MUC1 gene polymorphisms are associated with gastric cancer and pre-malignant gastric conditions [corrected].Anticancer Res. 2014 Dec;34(12):7167-75.
49	Inflammatory responses induced by Helicobacter pylori on the carcinogenesis of gastric epithelial GES? cells.Int J Oncol. 2019 Jun;54(6):2200-2210. doi: 10.3892/ijo.2019.4775. Epub 2019 Apr 9.
50	Trefoil factor family 2 expression inhibits gastric cancer cell growth and invasion invitro via interactions with the transcription factor Sp3.Int J Mol Med. 2016 Nov;38(5):1474-1480. doi: 10.3892/ijmm.2016.2739. Epub 2016 Sep 19.
51	Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma.J Med Microbiol. 2004 Jan;53(Pt 1):21-29. doi: 10.1099/jmm.0.05348-0.